Dosage of bDMARDs and tsDMARDs in AS, nr-axSpA, PsA and IBD
Category:
- Treatment
Efficacy of NSAIDs for the Treatment of Patients with Ankylosing Spondylitis
Category:
- Treatment
Efficacy of Traditional and COX-2 Selective NSAIDs in Axial SpA
Category:
- Treatment
NSAID Therapy in Ankylosing Spondylitis: Radiographic Progression
Category:
- Treatment
Continuous versus On-demand NSAID* Intake in AS: No Difference in Radiographic Progression in Spine
Category:
- Treatment
Different Effect of NSAIDs on Radiographic Spinal Progression in Patients with Normal and Elevated Acute Phase Reactants
Category:
- Treatment
Short-Term Safety of Traditional and COX-2 Selective NSAIDs in Axial SpA
Category:
- Treatment
Association of NSAID Use and Cardiovascular Risk in Ankylosing Spondylitis
Category:
- Treatment
Conventional DMARDs Are Largely Not Effective for the Treatment of Patients with AS
Category:
- Treatment
Injection of Corticosteroids into the Sacroiliac Joint of SpA Patients with Sacroiliitis
Category:
- Treatment
Systemic Steroids in Ankylosing Spondylitis
Category:
- Treatment
ASAS-EULAR Recommendations for the Treatment of Patients with axSpA with b- or tsDMARDs
Category:
- Treatment
ASAS-EULAR Recommendations for the Continuation of b- or tsDMARDs
Category:
- Treatment
ASAS 40 Response after 24 Weeks of Treatment of AS Patients with TNFalpha Blocking Agents*
Category:
- Treatment
ASAS 40 Response after 12 and 24 Weeks of Treatment of Axial SpA with Certolizumab pegol
Category:
- Treatment
Effect of TNF Inhibitors in Patients with Radiographic Axial SpA (Ankylosing Spondylitis)
Category:
- Treatment
Anti-TNFα Therapy in Patients with AS - Sustained Efficacy Over at Least 7 Years
Category:
- Treatment
Longterm Clinical Efficacy of TNFalpha-Blocker in AS Results over 8 years
Category:
- Treatment
Clinical Outcome after Withdrawal of Anti-TNF in Ankylosing Spondylitis and Response to Retreatment
Category:
- Treatment
Effectiveness of TNF alpha Blockers in Early Axial Spondyloarthritis in Daily Practice
Category:
- Treatment
NSAID-Sparing Effect of TNF-Inhibitors in Real Life in Early Axial SpA
Category:
- Treatment
Effectiveness of TNF alpha Blockers in Early Axial Spondyloarthritis in Daily Practice Regarding Active MRI Sacroiliitis
Category:
- Treatment
mSASSS, BASDAI, BASMI and BASFI in AS Patients Treated with TNF-blockers for up to 10 Years
Category:
- Treatment
Radiographic Progression and Change in the Functional Status in AS Patients Treated with TNF-blockers for up to 10 Years
Category:
- Treatment
Changes in the Functional Status and Spinal Mobility in Relation to Radiographic Progression and Disease Activity in AS Patients Treated with TNF-Blockers for up to 10 Years
Category:
- Treatment
Early Clinical Response Predicts Long-Term Treatment Outcome with Anti-TNF in Ankylosing Spondylitis
Category:
- Treatment
Predictive Value of a Combination of Parameters Indicating BASDAI 50 Response to Anti-TNFalpha-Therapy
Category:
- Treatment
Effect after 24 weeks Anti-TNFalpha-Therapy on a Productivity Score
Category:
- Treatment
ASSERT MRI Study: Example, Patient Before vs. After Therapy with Infliximab, STIR-Technique
Category:
- Treatment
Improvement from Baseline in MRI Activity Score (STIR) at Week 24
Category:
- Treatment
MRI of the Sacroiliac Joints Before and After Etanercept Treatment (STIR)
Category:
- Treatment
Sustained Improvement in MRI Outcomes in Patients with Axial SpA Treated with Certolizumab Pegol to Week 204
Category:
- Treatment
MRI of the Spine (STIR) Before and After Adalimumab Treatment
Category:
- Treatment
Anti-TNFalpha-Therapy over 2 Years Does not Inhibit Radiographic Progression in AS
Category:
- Treatment
Continuous Long-Term Anti-TNF Therapy Might not Lead to an Increase of New Bone Formation over 8 Years in AS
Category:
- Treatment
Anti-TNF Therapy Might Slow Radiographic Progression in AS: Data from an Observational Study
Category:
- Treatment
Radiographic Spinal Progression after 2 and 4 Years in Patients with AxSpA Treated with Certolizumab Pegol
Category:
- Treatment
Radiographic Spinal Progression after 2 and 4 Years in Patients with AxSpA Treated with Certolizumab Pegol
Category:
- Treatment
Long-Term Anti-TNF Therapy Inhibit Radiographic Progression in AS: Data from the Swiss Clinical Quality Management (SCQM) cohort
Category:
- Treatment
Long-Term Anti-TNF Therapy Inhibit Radiographic Progression in AS: Data from the Swiss Clinical Quality Management (SCQM) cohort
Category:
- Treatment
TNFi Reduce Spinal Radiographic Progression at least Partially by Uncoupling the Relation Between ASDAS and mSASSS
Category:
- Treatment
Good Response to Anti-TNF Agents is Associated with a Lower Spinal Radiographic Progression in the Next 2 Years
Category:
- Treatment
A Time-Shifted Effect of TNFi on Radiographic Spinal Progression in Axial SpA (1)
Category:
- Treatment
A Time-Shifted Effect of TNFi on Radiographic Spinal Progression in Axial SpA (2)
Category:
- Treatment
Inflammatory and Post-Inflammatory Lesions are Associated with New Bone Formation in AS
Category:
- Treatment